ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
8.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.Cancer medicine · 2022Pooled it
- Prognostic gene expression signature for high-grade serous ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2020Pooled it
- Transcriptome signatures for the identification of bevacizumab responders in ovarian cancer.Genome medicine · 2026Article
- Immunological and prognostic impact of NRF2 in high grade serous ovarian cancer.Genes and immunity · 2026Article
- Impact of Anatomical Site on RNA-Based Molecular Subtypes in Paired High-Grade Serous Ovarian Carcinoma Samples.Cancers · 2026Article
- Transcriptomic subtypes in high-grade serous ovarian cancer are driven by tumor cellular composition.bioRxiv : the preprint server for biology · 2026Article
- Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.Nature communications · 2026Article
- Metabolic Dependency on De Novo Pyrimidine Synthesis Is a Targetable Vulnerability in Platinum-Resistant Ovarian Cancer.Cancer research · 2026Article
- Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.Research square · 2025Article
- BeyondmedRxiv : the preprint server for health sciences · 2025Article
- Tumoroid model recreates clinically relevant phenotypes of high grade serous ovarian cancer (HGSC) cells, carcinoma associated fibroblasts, and macrophages.Research square · 2025Article
- Overcoming intra-tumoral heterogeneity for biomarker discovery in the high-grade serous ovarian cancer proteome.NPJ precision oncology · 2025Article
- Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Plasma-activated media selectively induces apoptotic death via an orchestrated oxidative stress pathway in high-grade serous ovarian cancer cells.Molecular oncology · 2025Article
- Leveraging Multi-omics to Disentangle the Complexity of Ovarian Cancer.Molecular diagnosis & therapy · 2025Review
- Quantifying intratumoral biomarker heterogeneity in tubo-ovarian high-grade serous carcinoma to optimize clinical translation.Scientific reports · 2025Article
- HE4 Might Participate in Extracellular Matrix Remodeling in Ovarian Cancer via Activation of Fibroblasts.Oncology research · 2025Article
- Cracking the code: predicting tumor microenvironment enabled chemoresistance with machine learning in the human tumoroid models.npj biomedical innovations · 2025Article
- Immune-molecular interactions in high-grade serous ovarian cancer distinguish long-term survivors.The Journal of clinical investigation · 2024Article
- Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high grade serous ovarian cancer subtype linkage to variable immune microenvironment.Journal of ovarian research · 2024Article
Corrections and comments
- Commented on by
Authors and funding
125 authors at 20 institutions in 12 countries.
Aline Talhouk *British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-7760-410X
Joshy George *The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0001-8510-8229
Chen Wang *Mayo Clinic, Division of Biomedical Statistics and Informatics, Department of Health Science Research, Rochester, Minnesota.ORCID 0000-0003-2638-3081
Timothy BuddenUniversity of NSW Sydney, School of Women's and Children's Health, Faculty of Medicine, Sydney, New South Wales, Australia.
Tuan Zea TanNational University of Singapore, Cancer Science Institute of Singapore, Center for Translational Medicine, Singapore, Singapore.ORCID 0000-0001-6624-1593
Derek S ChiuBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Stefan KommossTuebingen University Hospital, Department of Women's Health, Tuebingen, Germany.
Huei San LeongPeter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Stephanie ChenCedars-Sinai Medical Center, Center for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California.
Maria P IntermaggioUniversity of NSW Sydney, School of Women's and Children's Health, Faculty of Medicine, Sydney, New South Wales, Australia.
Blake GilksBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Tayyebeh M NazeranBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Mila VolchekRoyal Women's Hospital, Anatomical Pathology, Parkville, Victoria, Australia.
Wafaa ElatreDepartment of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
Rex C BentleyDepartment of Pathology, Duke University Hospital, Durham, North Carolina.
Janine SenzBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Amy LumBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Veronica ChowBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Hanwei SudderuddinBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Robertson MackenzieBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Samuel C Y LeongBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Geyi LiuBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Dustin JohnsonBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Billy ChenBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Aocs GroupPeter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Jennifer AlsopCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
Susana N BanerjeeThe Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Gynaecology Unit, London, United Kingdom.
Sabine BehrensGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.ORCID 0000-0002-9714-104X
Clara BodelonNCI, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland.ORCID 0000-0002-6578-2678
Alison H BrandDepartment of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
Louise BrintonNCI, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland.ORCID 0000-0003-3853-8562
Michael E CarneyDepartment of Obstetrics and Gynecology, University of Hawaii, John A. Burns School of Medicine, Honolulu, Hawaii.
Yoke-Eng ChiewCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.
Kara L Cushing-HaugenFred Hutchinson Cancer Research Center, Program in Epidemiology, Division of Public Health Sciences, Seattle, Washington.
Cezary CybulskiDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Darren EnnisImperial College London, Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, London, United Kingdom.
Sian FeredayPeter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Renée T FortnerGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.ORCID 0000-0002-1426-8505
Jesús García-DonasHM Hospitales Centro Integral Oncológico Clara Campal (HM CIOCC), Madrid, Spain.ORCID 0000-0001-7731-3601
Aleksandra Gentry-MaharajUniversity College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, United Kingdom.ORCID 0000-0001-7270-9762
Rosalind GlasspoolDepartment of Medical Oncology, Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-5000-1680
Teodora GoranovaCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Casey S GreeneDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-8713-9213
Paul HaluskaMayo Clinic, Department of Oncology, Rochester, Minnesota.
Holly R HarrisFred Hutchinson Cancer Research Center, Program in Epidemiology, Division of Public Health Sciences, Seattle, Washington.ORCID 0000-0002-2572-6727
Joy HendleyPeter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Brenda Y HernandezUniversity of Hawaii Cancer Center, Cancer Epidemiology Program, Honolulu, Hawaii.
Esther HerpelInstitute of Pathology and NCT Tissue Bank, University Hospital Heidelberg, Heidelberg, Germany.
Mercedes Jimenez-LinanAddenbrooke's Hospital NHS Trust, Department of Pathology, Cambridge, United Kingdom.
Chloe KarpinskyjUniversity College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, United Kingdom.
Scott H KaufmannMayo Clinic, Department of Oncology, Rochester, Minnesota.ORCID 0000-0002-4900-7145
Gary L KeeneyDivision of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Catherine J KennedyCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-4465-5784
Martin KöbelDepartment of Pathology and Laboratory Medicine, Foothills Medical Center, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-6615-2037
Jennifer M KoziakAlberta Health Services-Cancer Care, Calgary, Alberta, Canada.ORCID 0000-0001-5830-0397
Melissa C LarsonMayo Clinic, Division of Biomedical Statistics and Informatics, Department of Health Science Research, Rochester, Minnesota.
Jenny LesterDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.
Liz-Anne LewsleyCancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
Jolanta LissowskaM Sklodowska Curie National Research Institute of Oncology, Department of Cancer Epidemiology and Prevention, Warsaw, Poland.ORCID 0000-0003-2695-5799
Jan LubińskiDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Hugh LukUniversity of Hawaii Cancer Center, Cancer Epidemiology Program, Honolulu, Hawaii.
Geoff MacintyreCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Sven MahnerDepartment of Obstetrics and Gynecology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
Iain A McNeishImperial College London, Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, London, United Kingdom.ORCID 0000-0002-9387-7586
Janusz MenkiszakDepartment of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland.ORCID 0000-0001-8279-7196
Nikilyn NevinsDepartment of Gynaecological Oncology, Westmead Hospital and Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.
Ana OsorioCentro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Oleg OszurekDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
José PalaciosHospital Universitario Ramón y Cajal, Pathology Department. IRYCIS. CIBERONC. Universidad de Alcalá, Madrid, Spain.
Samantha HinsleyCancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0001-6903-4688
Celeste L PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.
Malcolm C PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.ORCID 0000-0003-4891-1199
Anna M PiskorzCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Isabelle Ray-CoquardCentre Leon Berard and University Claude Bernard Lyon 1, Lyon, France.
Valerie RheniusCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
Cristina Rodriguez-AntonaSpanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain.ORCID 0000-0001-8750-7338
Raghwa SharmaPathology West ICPMR Westmead, Westmead Hospital, The University of Sydney, Sydney, New South Wales, Australia.
Mark E ShermanDepartment of Health Sciences Research, Mayo Clinic College of Medicine, Jacksonville, Florida.
Dilrini De SilvaCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Naveena SinghDepartment of Pathology, Barts Health National Health Service Trust, London, United Kingdom.
Peter SinnDepartment of Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0003-2836-6699
Dennis SlamonDivision of Hematology and Oncology, Department of Medicine, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California.
Honglin SongCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
Helen SteedDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Royal Alexandra Hospital, Edmonton, Alberta, Canada.
Euan A StronachImperial College London, Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, London, United Kingdom.
Pamela J ThompsonCedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Los Angeles, California.
Aleksandra TołoczkoDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Britton TrabertNCI, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland.ORCID 0000-0002-1539-6090
Nadia TraficantePeter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Chiu-Chen TsengDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Martin WidschwendterDepartment of Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom.ORCID 0000-0002-7778-8380
Lynne R WilkensUniversity of Hawaii Cancer Center, Cancer Epidemiology Program, Honolulu, Hawaii.
Stacey J WinhamMayo Clinic, Division of Biomedical Statistics and Informatics, Department of Health Science Research, Rochester, Minnesota.ORCID 0000-0002-8492-9102
Boris WinterhoffDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Minnesota.
Alicia Beeghly-FadielDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Javier BenitezCentro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Andrew BerchuckDepartment of Gynecologic Oncology, Duke University Hospital, Durham, North Carolina.
James D BrentonCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-5738-6683
Robert BrownDivision of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.ORCID 0000-0001-7960-5755
Jenny Chang-ClaudeGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.ORCID 0000-0001-8919-1971
Georgia Chenevix-TrenchQIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, Queensland, Australia.
Anna deFazioCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-0057-4744
Peter A FaschingDivision of Hematology and Oncology, Department of Medicine, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California.ORCID 0000-0003-4885-8471
María J GarcíaSpanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain.
Simon A GaytherCedars-Sinai Medical Center, Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Los Angeles, California.
Marc T GoodmanCedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Los Angeles, California.
Jacek GronwaldDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Michelle J HendersonChildren's Cancer Institute, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
Beth Y KarlanDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.
Linda E KelemenHollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-4362-9784
Usha MenonUniversity College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, United Kingdom.ORCID 0000-0003-3708-1732
Sandra OrsulicDavid Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.
Paul D P PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8494-732X
Nicolas WentzensenNCI, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Joellen M SchildkrautDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Mary Anne RossingFred Hutchinson Cancer Research Center, Program in Epidemiology, Division of Public Health Sciences, Seattle, Washington.
Gottfried E KonecnyDivision of Hematology and Oncology, Department of Medicine, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California.
David G HuntsmanBritish Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
Ruby Yun-Ju HuangNational University of Singapore, Cancer Science Institute of Singapore, Center for Translational Medicine, Singapore, Singapore.
Ellen L Goode *Division of Epidemiology, Department of Health Science Research, Mayo Clinic, Rochester, Minnesota. m.anglesio@ubc.ca David.bowtell@petermac.org jen.doherty@hci.utah.edu s.ramus@unsw.edu.au egoode@mayo.edu.
Susan J Ramus *University of NSW Sydney, School of Women's and Children's Health, Faculty of Medicine, Sydney, New South Wales, Australia. m.anglesio@ubc.ca David.bowtell@petermac.org jen.doherty@hci.utah.edu s.ramus@unsw.edu.au egoode@mayo.edu.ORCID 0000-0003-0005-7798
Jennifer A Doherty *Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. m.anglesio@ubc.ca David.bowtell@petermac.org jen.doherty@hci.utah.edu s.ramus@unsw.edu.au egoode@mayo.edu.ORCID 0000-0002-1454-8187
David D Bowtell *Peter MacCallum Cancer Center, Melbourne, Victoria, Australia. m.anglesio@ubc.ca David.bowtell@petermac.org jen.doherty@hci.utah.edu s.ramus@unsw.edu.au egoode@mayo.edu.
Michael S Anglesio *British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada. m.anglesio@ubc.ca David.bowtell@petermac.org jen.doherty@hci.utah.edu s.ramus@unsw.edu.au egoode@mayo.edu.ORCID 0000-0003-1639-5003
Vancouver General Hospital · CACancer Research UK Cambridge Center · GBCedars-Sinai Medical Center · USPomeranian Medical University · PLPeter MacCallum Cancer Centre · AUUniversity of Southern California · USWestmead Hospital · AUMayo Clinic · USNational Cancer Institute · USOvarian Cancer Action · GBSpanish National Cancer Research Centre · ESUniversity of British Columbia · CACancer Center of Hawaii · USMayo Clinic in Florida · USMRC Clinical Trials Unit at UCL · GBUniversity of California, Los Angeles · USCancer Institute of New South Wales · AUCancer Research UK Clinical Trials Unit · GBDuke University Hospital · USGerman Cancer Research Center · DE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MUCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MHormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5MUTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6MShared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9MUCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0MUniversity of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0MIdentifying Prognostic Markers and Therapeutic Targets for Serous Ovarian CancerR01CA172404 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RAMUS, SUSAN J · 2013 to 2017
$2.9MCharacterizing Molecular Subtypes of Ovarian Cancer in African-American WomenR01CA200854 · NCI · UNIVERSITY OF UTAH · PI DOHERTY, JENNIFER A., SCHILDKRAUT, JOELLEN M. · 2016 to 2021
$2.8MEpidemiologic factors and survival by molecular subtypes of ovarian cancerR01CA168758 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DOHERTY, JENNIFER A., ROSSING, MARY ANNE · 2013 to 2016
$2.6MPCOS, Type II diabetes and ovarian cancer riskK22CA193860 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HARRIS, HOLLY RUTH · 2016 to 2018
$554kCancer Research UK 13086Cancer Research UK 15601Cancer Research UK 22905Medical Research Council MC_UU_12023/20NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCI NIH HHS K22 CA193860NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA034196NCI NIH HHS P30 CA042014NCI NIH HHS P30 CA071789NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA168758NCI NIH HHS R01 CA172404NCI NIH HHS R01 CA200854
Abstract
purposeGene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by nonstandardized methods, which are not applicable in a clinical setting. We sought to generate a clinical grade minimal gene set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported subtype-associated features. EXPERIMENTAL
designAdopting two independent approaches, we derived and internally validated algorithms for subtype prediction using published gene expression data from 1,650 tumors. We applied resulting models to NanoString data on 3,829 HGSOCs from the Ovarian Tumor Tissue Analysis consortium. We further developed, confirmed, and validated a reduced, minimal gene set predictor, with methods suitable for a single-patient setting.
resultsGene expression data were used to derive the predictor of high-grade serous ovarian carcinoma molecular subtype (PrOTYPE) assay. We established a
conclusionsWe validated the PrOTYPE assay following the Institute of Medicine guidelines for the development of omics-based tests. This fully defined and locked-down clinical grade assay will enable trial design with molecular subtype stratification and allow for objective assessment of the predictive value of HGSOC molecular subtypes in precision medicine applications.
Indexed as
AgedAlgorithmsCystadenoma, SerousFemaleGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingMiddle AgedNeoplasm GradingNeoplasm ProteinsNeoplasm, ResidualOvarian NeoplasmsTranscriptomeNeoplasm Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.